|
Volumn 14, Issue 1, 2003, Pages 80-83
|
The design of prophylactic trials for HlV: The case of microbicides
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIINFECTIVE AGENT;
AGENTS USED INTRAVAGINALLY;
PLACEBO;
TOPICAL ANTIINFECTIVE AGENT;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
HIGH RISK POPULATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INFECTION CONTROL;
PRIORITY JOURNAL;
PROPHYLAXIS;
REVIEW;
RISK BENEFIT ANALYSIS;
VIRUS TRANSMISSION;
ARTICLE;
CONDOM;
DISEASE TRANSMISSION;
DRUG EFFECT;
FEMALE;
INTRAVAGINAL DRUG ADMINISTRATION;
METHODOLOGY;
RANDOMIZED CONTROLLED TRIAL;
SEXUALLY TRANSMITTED DISEASE;
UNITED STATES;
VIROLOGY;
ADMINISTRATION, INTRAVAGINAL;
ANTI-INFECTIVE AGENTS, LOCAL;
CONDOMS, FEMALE;
FEMALE;
HIV;
HIV INFECTIONS;
HUMANS;
PLACEBOS;
RANDOMIZED CONTROLLED TRIALS;
RESEARCH DESIGN;
SEXUALLY TRANSMITTED DISEASES, VIRAL;
UNITED STATES;
VAGINAL CREAMS, FOAMS, AND JELLIES;
|
EID: 0037209186
PISSN: 10443983
EISSN: None
Source Type: Journal
DOI: 10.1097/00001648-200301000-00018 Document Type: Review |
Times cited : (22)
|
References (8)
|